Talking about more revenue, the animal related product CPH are releasing 3rd qtr this year is going to be interesting. I feel it is currently underestimated on what the market demand will be, especially in the European and Northern American markets. People, human nature have a great emotional attachment to their pets and if treatment is proven to be successful in pain relief ,eating disorders etc as a natural alternative to other synthetic treatments that may have negative side effects then this product will be huge. One of the reasons I invested in CPH was because of this opportunity. Looking forward to the launch in a couple of months and the cash cow to be medicated and flowing.
- Forums
- ASX - By Stock
- Ann: Asia Investor Roadshow
Talking about more revenue, the animal related product CPH are...
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online